1) anticoagulant
抗栓剂
2) chimeric antithrombotic
嵌合抗栓剂
3) antithrombotic therapy
抗栓
1.
Objective The aim of the study was to assess the effect and safety ofTraditional Chinese Medicine which activating blood to resolve stagnationcombined with antithrombotic therapy by observing the effect and safety ofTraditional Chinese Medicine which activating blood to resolve stagnationcombined with antithrombotic therapy with ACS patients.
目的观察活血化瘀类中药联合抗栓治疗在ACS患者的疗效性和安全性，旨在结合我国国情，评估活血化瘀类中药联合抗栓治疗的获益和风险。
4) Antithrombotic
抗栓治疗
1.
Choice of medicine and monitoring in antithrombotic treatment for atrial fibrillation;
心房颤动抗栓治疗的药物选择及监测
5) kangshuanhao
抗栓号
1.
OBJECTIVE: To explore the clinical outcome of kangshuanhao in the treatment of unstable angina pectoris and to discuss the action of IL-6 in the occurrence and development of unstable angina pectoris and the effect of kangshuanhao on IL-6.
目的:观察抗栓号治疗不稳定型心绞痛炎症反应(UA)的临床疗效,探讨IL-6在UA发生、发展中的作用,以及抗栓号对UA患者IL-6的影响。
6) Decorsin
抗栓肽
1.
Cloning and Expression of An Antithrombolytic Peptide Decorsin in E.Coli;
抗栓肽基因的克隆和表达
2.
The fusion protein of MBP\|decorsin was produced by IPTG induction in E.
将人工合成的寡核苷酸片段进行体外连接 ,得到编码抗栓肽 (decorsin)的cDNA 。
3.
A recombinant chimeric plasminogen activator (dscu PA(B)) was constructed, consisting of the decorsin (platelet aggregation inhibitor), fused via a 15 amino acid linker (Gly\-4Ser)\-3 sequence to the N terminal of the B chain of urokinase (comprising Leu159 through Leu 411).
通过基因工程重组技术 ,将抗栓肽 (decorsin)基因与尿激酶的B链即scu PA(B)基因用柔性Linker((Gly4Ser) 3 )融合在一起 ,构建新的嵌合体基因dscuPA(B) ,在大肠杆菌Rosetta(DE3)plysS中通过IPTG诱导表达 ,并考察了重组质粒在Rosetta(DE3)plysS在传代中的分离稳定性。
参考词条
补充资料：α-型抗结晶抗絮凝酞菁蓝
分子式：
CAS号：
性质：红光蓝色粉末。属于稳定α-型晶相。具有良好的耐溶剂稳定性。在溶剂中不发生色光与晶型的转变。日晒牢度7～8级。以铜酞菁母体与甲醛缩合，其产物与N-羟甲基苯二甲酰亚胺反应，生成的N-羟甲基苯二甲酰亚胺衍生物与铜酞菁母体以1:10质量比混合，再经酸溶，析出，过滤，漂洗，干燥得最终产物。用于高档油墨、涂料及塑料的着色。
CAS号：
性质：红光蓝色粉末。属于稳定α-型晶相。具有良好的耐溶剂稳定性。在溶剂中不发生色光与晶型的转变。日晒牢度7～8级。以铜酞菁母体与甲醛缩合，其产物与N-羟甲基苯二甲酰亚胺反应，生成的N-羟甲基苯二甲酰亚胺衍生物与铜酞菁母体以1:10质量比混合，再经酸溶，析出，过滤，漂洗，干燥得最终产物。用于高档油墨、涂料及塑料的着色。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。